Suppliers / Hanlim Pharmaceutical

Hanlim Pharmaceutical

South Korea 2 duplicate records merged Updated 9 July 2026

Hanlim Pharmaceutical is a finished-dose manufacturer based in South Korea. It appears in 20 regulatory filings across 5 regulators, without an active US DMF or CEP on file. Its filings concentrate with DIGEMAPS (DO), NPRA (MY) and NMPA (CN).

0
active US DMFs
0
valid CEPs
0
registered plants
20
filings across 5 regulators

Filings and GMP by regulator

Regulator Filings GMP certificates
DIGEMAPS (DO) 10 None
NPRA (MY) 4 None
NMPA (CN) 2 None
NAFDAC (NG) 2 None
UZPHARM (UZ) 2 None

Limited public record

Beyond the filing counts above, the public registers hold no plant, inspection or portfolio detail for this company as at 9 July 2026. We report that as a gap rather than inferring an answer.

Questions about Hanlim Pharmaceutical

Does Hanlim Pharmaceutical hold a US DMF or a CEP?
No active US drug master file or valid CEP is on record for Hanlim Pharmaceutical. It does have 20 filings with 5 regulators, so it is registered, just not with the two strong registers buyers usually screen on.
Where does Hanlim Pharmaceutical file?
Filings are on record with DIGEMAPS (DO), NPRA (MY), NMPA (CN), NAFDAC (NG) and 1 other regulator, 20 in total.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Hanlim Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability